206 related articles for article (PubMed ID: 33675400)
1. Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis.
Del Giudice F; Busetto GM; Gross MS; Maggi M; Sciarra A; Salciccia S; Ferro M; Sperduti I; Flammia S; Canale V; Chung BI; Conti SL; Eisenberg ML; Skinner EC; De Berardinis E
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3073-3080. PubMed ID: 33675400
[TBL] [Abstract][Full Text] [Related]
2. Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis.
Del Giudice F; Flammia RS; Chung BI; Moschini M; Pradere B; Mari A; Soria F; Albisinni S; Krajewski W; Szydełko T; Laukhtina E; D'Andrea D; Gallioli A; Mertens LS; Maggi M; Sciarra A; Salciccia S; Ferro M; Scornajenghi CM; Asero V; Cattarino S; De Angelis M; Cacciamani GE; Autorino R; Pandolfo SD; Falagario UG; D'Altilia N; Mancini V; Chirico M; Cinelli F; Bettocchi C; Cormio L; Carrieri G; De Berardinis E; Busetto GM; On Behalf Of European Association Of Urology Eau-Young Academic Urologists Yau Urothelial Cancer Working Party
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205635
[TBL] [Abstract][Full Text] [Related]
3. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY;
Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.
Witjes JA; Dalbagni G; Karnes RJ; Shariat S; Joniau S; Palou J; Serretta V; Larré S; di Stasi S; Colombo R; Babjuk M; Malmström PU; Malats N; Irani J; Baniel J; Cai T; Cha E; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Pisano F; Gontero P; Sylvester R
Urol Oncol; 2016 Nov; 34(11):484.e19-484.e25. PubMed ID: 27639776
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
6. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.
D'Andrea D; Soria F; Abufaraj M; Pones M; Gontero P; Machado AT; Waksman R; Enikeev DV; Glybochko PV; Adonias SP; Nahas WC; Shariat SF; Chade DC
Clin Genitourin Cancer; 2020 Feb; 18(1):20-25.e2. PubMed ID: 31786120
[TBL] [Abstract][Full Text] [Related]
8. The comparison of different BCG strains in the intravesical treatment of non-muscle invasive urothelial carcinoma of urinary bladder-A real-world practice.
Chen YK; Huang EY; Chang YH; Kuo JY; Chung HJ; Wu HH; Lin TP; Lin CC; Fan YH; Huang IS; Lin ATL; Huang WJ
J Chin Med Assoc; 2022 Sep; 85(9):928-934. PubMed ID: 36150105
[TBL] [Abstract][Full Text] [Related]
9. Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer.
Steinberg RL; Brooks NA; Thomas LJ; Mott SL; O'Donnell MA
Urol Oncol; 2017 May; 35(5):201-207. PubMed ID: 28041998
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the oncological outcomes of three different bacillus Calmette-Guérin strains in patients with high-grade T1 non-muscle-invasive bladder cancer.
Nowak Ł; Krajewski W; Moschini M; Chorbińska J; Poletajew S; Tukiendorf A; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Orlando R; Di Trapani E; Alvarez-Maestro M; Simone G; Zamboni S; Simeone C; Marconi MC; Mastroianni R; Piszczek R; Xylinas E; Zdrojowy R;
Arab J Urol; 2021 Jan; 19(1):78-85. PubMed ID: 33763252
[TBL] [Abstract][Full Text] [Related]
11. Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC).
Farah NB; Ghanem R; Amr M
BMC Urol; 2014 Jan; 14():11. PubMed ID: 24468269
[TBL] [Abstract][Full Text] [Related]
12. Comparing Clinical Efficacy of Different Bacillus Calmette-Guérin Strains in Patients With T1 High Grade Bladder Cancer.
Yu SH; Wang CY; Wang SS; Li JR; Hung SC
Anticancer Res; 2024 Mar; 44(3):1299-1307. PubMed ID: 38423631
[TBL] [Abstract][Full Text] [Related]
13. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
14. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
15. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
16. The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?
Hofbauer SL; Shariat SF; Chade DC; Sarkis AS; Ribeiro-Filho LA; Nahas WC; Klatte T
Urol Int; 2016; 96(1):46-50. PubMed ID: 26555711
[TBL] [Abstract][Full Text] [Related]
17. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.
Palou J; Pisano F; Sylvester R; Joniau S; Serretta V; Larré S; Di Stasi S; van Rhijn B; Witjes AJ; Grotenhuis A; Colombo R; Briganti A; Babjuk M; Soukup V; Malmstrom PU; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Varkarakis J; Bartoletti R; Dalbagni G; Shariat SF; Xylinas E; Karnes RJ; Gontero P
World J Urol; 2018 Oct; 36(10):1621-1627. PubMed ID: 29721611
[TBL] [Abstract][Full Text] [Related]
18. Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials.
Quan Y; Jeong CW; Kwak C; Kim HH; Kim HS; Ku JH
Medicine (Baltimore); 2017 Oct; 96(42):e8300. PubMed ID: 29049231
[TBL] [Abstract][Full Text] [Related]
19. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
20. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
